At Goodwin, we partner with our clients to practice law with integrity, ingenuity, agility, and ambition. Our 1,600 lawyers across the United States, Europe, and Asia excel at complex transactions, high-stakes litigation and world-class advisory services in the technology, life sciences, real estate, private equity, and financial industries. Our unique combination of deep experience serving both the innovators and investors in a rapidly changing, technology-driven economy sets us apart.
This week, Biogen announced that the European Commission has approved TOFIDENCE, a tocilizumab biosimilar referencing Roche's ROACTEMRA. TOFIDENCE was approved by the FDA in September 2023.
To print this article, all you need is to be registered or login on Mondaq.com.
This week, Biogen announced that the European
Commission has approved TOFIDENCE, a tocilizumab biosimilar
referencing Roche's ROACTEMRA. TOFIDENCE was approved by the FDA in September
2023.
TOFIDENCE is an intravenous formulation of an interleukin-6
receptor antagonist, and is approved for the treatment of moderate
to severe active rheumatoid arthritis, polyarticular juvenile
idiopathic arthritis, systemic juvenile idiopathic arthritis and
COVID-19. Under a 2021 licensing agreement between Biogen and
Bio-Thera, Biogen has exclusive regulatory, manufacturing, and
commercial rights to TOFIDENCE in all countries, except China.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
